TrialBMJ open2015

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study.

Thomas Fremming Dejgaard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.